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Abstract
Background: Up to 30 % of children with acute asthma are refractory to initial therapy, and 84 % of this
subpopulation needs hospitalization. Finding safe, noninvasive, and effective strategies to treat this high-risk
group would substantially decrease hospitalizations, healthcare costs, and the psycho-social burden of the
disease.
Whereas intravenous magnesium (Mg) is effective in severe refractory asthma, its use is sporadic due to safety
concerns, with the main treatment goal being to prevent intensive care unit admission. In contrast, nebulized
Mg is noninvasive, allows higher pulmonary drug concentrations, and has a much higher safety potential due
to the lower rate of systemic delivery. Previous studies of inhaled Mg show disparate results due to the use
of unknown/inefficient delivery methods and other methodological flaws.
Methods/Design: The study is a randomized double-blind controlled trial in seven Canadian pediatric Emergency
Departments (two-center pilot 2011 to 2014, Canada-wide November 2014 to December 2017). The trial will include
816 otherwise healthy children who are 2 to 17 years old, having had at least one previous wheezing episode, have
received systemic corticosteroids, and have a Pediatric Respiratory Assessment Measure (PRAM)≥ 5 points after three
salbutamol and ipratropium treatments for a current acute asthma exacerbation. Eligible consenting children will
receive three experimental treatments of nebulized salbutamol with either 600 mg of Mg sulfate or placebo 20 min
apart, using an Aeroneb Go nebulizer, which has been shown to maximize pulmonary delivery while maintaining
safety. The primary outcome is hospitalization within 24 h of the start of the experimental therapy for persistent
respiratory distress or supplemental oxygen. Secondary outcomes include all-cause hospitalization within 24 h,
PRAM, vital signs, number of bronchodilator treatments by 240 min, and the association between the
difference in the primary outcome between the groups, age, gender, baseline PRAM, atopy, and “viral induced
wheeze” phenotype (Fig. 1).
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Discussion: If effective, inhaled Mg may represent an effective strategy to minimize morbidity in pediatric
refractory acute asthma. Unlike previous works, this trial targets nonresponders to optimized initial therapy
who are the most likely to benefit from inhaled Mg. Future dissemination of results will include knowledge
translation, incorporation into a Cochrane Review, presentation at scientific meetings, and a peer-reviewed
publication.
Trial registration: NCTO1429415, registered 2 September 2011.
Keywords: Randomized controlled trial, children, acute asthma, magnesium
Background
Acute asthma is a leading cause of pediatric emergency
department (ED) visits and of pediatric hospitalizations
[1], with the annual asthma expenditures in the United
States exceeding $37 billion [2]. In 2005, 754,000 pediatric
ED asthma visits were reported in the US [3, 4], and 27 %
of these resulted in hospitalization [4]. Practice guidelines
recommend high dose ß2 agonists, inhaled anticholiner-
gics, and oral corticosteroids to manage major acute
exacerbations [5–9]. However, this initial optimal therapy
[9–11] is not always effective [12] because up to 30 % of
patients with asthma are resistant to initial bronchodila-
tion [13] in part due to ß2 adrenoreceptor gene
polymorphism [14–32], and gene polymorphisms also im-
pact the frequently delayed response to corticosteroids
[33–35]. Finding further effective strategies to decrease
pediatric asthma hospitalizations in this high-risk popula-
tion is necessary.
Magnesium sulfate (Mg) produces rapid bronchodila-
tion by multiple mechanisms [36–39] and can be given
either intravenously (IV) or by nebulization. Two key
meta-analyses of adult and pediatric trials have con-
firmed that the addition of IV Mg to routine therapy sig-
nificantly decreases hospitalizations and improves lung
function [40, 41]. These authors, as well as various
asthma guidelines, recommend that IV Mg be consid-
ered in children not responding to initial management
[40, 42–44]. However, IV Mg is used infrequently and
often as a last resort [45, 46]. In contrast, the nebuliza-
tion route is noninvasive and offers a major advantage of
targeted delivery to the lower airway and less potential
for side effects [47]. However, the benefit of nebulized
Mg has not been well established.
The investigation of the efficacy of nebulized Mg has
been limited, with disparate results. The dose of Mg varied
seven-fold among studies [48–60], and only one study
[48] limited participants to nonresponders to bronchodila-
tors. Two meta-analyses of mainly adult studies have
found a trend toward reduction in hospitalizations in pa-
tients given nebulized Mg [40, 61], with the recent
Cochrane review reaching similar conclusions [59]. The
main limitations of past pediatric studies are failure to
limit participants to nonresponders to bronchodilators,
inadequate use of anticholinergics, use of inefficient deliv-
ery methods, and small sample size [49, 58, 60, 62]. In
contrast, this study focuses on the poor responders to op-
timized baseline acute asthma therapy. This group is at
the highest risk of hospitalization and the most likely to
benefit from nebulized Mg intervention. Furthermore,
previous studies have used nebulizers of suboptimal/un-
known efficacy. In contrast, the device used in this study
has been pre-tested and shown to deliver a considerably
greater proportion of the drug into the lungs compared to
the conventional nebulizers.
Research questions and study hypothesis
Primary question
The primary question is whether, in children 2–17
years of age with acute asthma who have persistent
moderate to severe airway obstruction despite maxi-
mized initial bronchodilator and steroid therapy, a re-
duction can be achieved in the probability of
hospitalization within 24 h of starting experimental
therapy. Specifically, this trial compares those patients
who receive three nebulized Mg and salbutamol treat-
ments to those receiving only nebulized salbutamol.
Secondary questions
The trial seeks to determine the following for these
treatment modalities:
a) Is there a difference in the probability of all-cause
hospitalization within 24 h of starting therapy?
b) Is there a difference in the changes in the validated
Pediatric Respiratory Assessment Measure (PRAM),
respiratory rate, oxygen saturation, and blood
pressure to 240 min?
c) Does the treatment effect with respect to primary
outcome vary among the subgroups defined by the
following variables: age, sex, pre-randomization
PRAM score, personal history of atopy and “viral-in-
duced wheeze” phenotype?
Hypothesis
We hypothesize that the children with PRAM ≥5 points
after optimized initial inhaled bronchodilator and systemic
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steroid therapy who are given nebulized Mg in addition to
nebulized salbutamol will have a significantly lower prob-
ability of hospitalization compared to those given salbuta-
mol only.
Methods/Design
Study design and population
This is a seven-center, randomized, double-blind con-
trolled trial. Two study groups are compared: nebulized
salbutamol with Mg sulfate and nebulized salbutamol
with placebo. This study has received approval by the
Research Ethics Board of the Hospital for Sick Children.
Furthermore, local Research Ethics Boards have ap-
proved the study at all participating sites (see Additional
file 1). A written informed consent and assent where
appropriate is being obtained from all study participants.
All otherwise healthy children 2–17 years of age with
a past history of asthma/recurrent wheeze arriving in the
ED when the study nurses are on duty with a presenting
PRAM ≥5 are considered potentially eligible. Following
assessment by the ED physician, the patients receive
oral/IV corticosteroid plus three salbutamol and ipratro-
pium inhalations according to the local management
guidelines [63–68]. If the PRAM is still ≥5 after the ini-
tial therapy, the study nurse confirms eligibility, mea-
sures the pre-randomization PRAM score, and obtains
informed consent.
PRAM score
PRAM is a validated 12-point clinical asthma severity
score [69], exhibits the most comprehensive measure-
ment properties of all asthma scores [70], and has been
successfully used as an outcome in major trials [71]. It is
the only score with demonstrated criterion validity,
using respiratory resistance as the gold standard [72].
PRAM has been validated in both preschool and school-
aged children who have been assessed in the ED for
asthma and has a strong association with admission
[73]. The score has inter-rater reliability consistently
above 70 % [73] and is currently implemented in virtu-
ally all pediatric EDs across Canada. Children with
PRAM ≥5 following initial bronchodilator therapy have
at least a 30 % probability of hospitalization and repre-
sent 84 % of all acute asthma admissions in children. All
participating EDs now measure the PRAM score as part
of routine clinical assessment in their EDs in children
with acute asthma. Because Calgary is situated 1000 m
above sea level, oxygen saturations there can be ex-
pected to be approximately 2 % lower than in Toronto
(International Civil Aviation Organization, Manual of
the ICAO Standard Atmosphere, Doc 7488-CD, Third
Edition, 1993, ISBN 92-9194-004-6). Therefore, the oxy-
gen saturation component of the PRAM is adjusted in
Calgary.
Inclusion criteria
Inclusion criteria are (1) 2 to 17 years of age, (2) diagno-
sis of asthma/reactive airways/viral-induced wheeze plus
at least one prior acute episode of wheezing treated with
inhaled ß2 agonists or oral corticosteroids, (3) persistent
moderate to severe airway obstruction after oral steroid
and three doses of salbutamol and ipratropium, defined
as a PRAM ≥5 [73].
Exclusion criteria
Exclusion criteria are (1) no past history of wheezing or
bronchodilator therapy; (2) prior IV Mg therapy during
the index visit; (3) critically ill children requiring imme-
diate intubation; (4) coexistent renal, chronic pulmonary,
neurologic, cardiac, or systemic disease; (5) children who
in the opinion of the treating physician require a chest
radiograph due to atypical clinical presentation and are
diagnosed to have lobar consolidation with pneumonia,
felt to be the primary cause of respiratory distress; (6)
known hypersensitivity to Mg sulfate; (7) patients previ-
ously enrolled; (8) insufficient command of the English
or French language; and (9) lack of a phone.
Delivery device
To ensure adequate delivery of the experimental treat-
ment into the lungs, we have pre-tested the Aeroneb™
Go Micropump Nebulizer along with the Idehaler™
Pocket system without valves that connects with a face-
mask in vitro and in vivo. We found that this device de-
posited 20 % of the charge dose compared to 4 % by
conventional nebulizers, while also maintaining accept-
able osmolarity and safety [74]. This device has been dis-
tributed to all participating sites, related training
provided, and Health Canada approval obtained. All ex-
perimental treatments are delivered with this device.
This device is fully licensed both in the United States
and in Europe and is currently awaiting license approval
in Canada. We do not anticipate any difficulties with its
official adoption by the time this trial is concluded.
Sample selection
Children presenting to the collaborating EDs at The
Hospital for Sick Children, Children’s Hospital of
Eastern Ontario, Ste Justine’s Hospital, Alberta Chil-
dren’s Hospital, Stollery Hospital, Children’s Hospital of
Winnipeg and the B.C. Children’s Hospital who meet eli-
gibility criteria are approached for enrollment when the
research nurses are on duty. The research nurses keep a
log of all children presenting to the ED with acute
asthma during the study period whether randomized or
not in order to assess the generalizability of the study.
All aforementioned hospitals are tertiary care centers,
which see the entire clinical and demographic spectrum
of the asthma population.
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Pre-study screening and baseline evaluation
All previously healthy children 2 and 17 years of age
with acute asthma have a PRAM score measured in tri-
age. Those meeting local ED criteria for enhanced
therapy receive either oral dexamethasone, oral prednis-
olone/prednisone, or IV hydrocortisone plus three salbu-
tamol and ipratropium inhalations via a Metered Dose
Inhaler/Valved Holding Chamber (MDI/VHC)/nebulizer
according to the local asthma pathway and 20 min apart.
Study procedures
At the conclusion of the three baseline inhalations, the
research nurse assesses eligibility and measures the pre-
randomization PRAM score. Eligible children with
PRAM ≥5 are approached, and informed consent is ob-
tained. Subjects are randomly allocated to receive three
consecutive nebulizations of salbutamol with either
diluted Mg sulfate or diluted 5.5 % saline placebo
20 min apart [48] using the Aeroneb™ Go Micropump
Nebulizer along with the Idehaler™ Pocket system. Spe-
cifically, each treatment utilizes 600 mg (1.2 mL) of Mg
sulfate or 1.2 mL 5.5 % saline, 5 mg (1 mL) of salbuta-
mol, and 3.8 mL of sterile water (Fig. 1).
Randomization and masking
The Research Coordinating Pharmacist at SickKids pro-
duced Master Randomization tables, stratified by site
and age (≥6 years versus less), using a permuted block
randomization of six and eight in a 1:1 ratio of active
Mg sulfate to placebo, using random number generating
software. The Master Randomization tables are held at
the site Research Pharmacies. Consecutively numbered
kits are prepared by each pharmacy according to the
step-by-step procedure manual provided by Research
Fig. 1 Flow diagram of participant study flow. The intervention consists of two treatment arms with solutions of identical osmolarity consisting of
inhaled salbutamol with Mg sulfate (experimental arm) and with equivalent saline placebo (control arm). The primary outcome is hospitalization
to inpatient unit for asthma-related symptoms within 24 h of randomization. *PRAM Pediatric Respiratory Assessment, **Mg magnesium
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Coordinating Pharmacist at SickKids. Upon receiving
the informed consent, the study nurse obtains the next
appropriate numbered study kit from the locked re-
search fridge in the ED (Mg has to be refrigerated) and
enters the number in the confidential logbook. Since Mg
sulfate solution is hypertonic, 5.5 % saline was chosen as
a placebo. Using sterile water as a top-up diluent in both
arms produces solutions of identical isotonicity
380 mOsm/L in both study groups. Because the depos-
ition of inhaled drugs is weight-independent [64], a uni-
form Mg dose is used in all children.
The patients, research nurses and ED physicians are
blinded to the treatment assignment. Only the pharma-
cies are unblinded. Each site is given detailed require-
ments for drug accountability and handling to ensure
compliance with Health Canada regulations. The active
Mg and placebo hypertonic saline mixture with salbuta-
mol and sterile water are very similar in volume, color,
taste, and smell when nebulized (tested in the research
pharmacy at SickKids). To assess blinding, the research
nurse and parents are asked at the conclusion of the ex-
perimental therapy which intervention they think the
child had received.
In case of increasing respiratory distress, IV Mg may
be given after the experimental therapy, provided the pa-
tient is not hypotensive. In the unlikely event that the
patient develops hypotension requiring therapy or apnea
and the ED physician feels that the experimental therapy
cannot be safely continued, further doses of the experi-
mental treatment are stopped. If these Mg side effects
are also accompanied by severe distress and additional
IV Mg is warranted, the code may be broken for that pa-
tient. Unblinding will only occur if the clinical treatment
of the patient will change because the physician knows
which arm of the study the patient was previously en-
rolled. The study PI/local PI and the study nurses will
remain blinded. No patients participating in our inhaled
Mg study received experimental therapy unblinded.
The study nurses also keep continuous study logs with
the characteristics and outcome of the participating and
nonparticipating eligible acute asthmatics ≥2 years of
age; these logs will also be used to track missed patients,
those excluded for criteria, and patients who refused
participation, which will help document any selection
bias.
After the intervention
Following the study medication, the patients continue to
receive further salbutamol as frequently as clinically
warranted as per the treating ED physician. Disposition
is also determined by blinded ED physicians. Discharged
patients receive a prescription for inhaled salbutamol
every 4 h as necessary for the next week and daily oral
corticosteroid according to local practice. All participating
families receive instructions to visit their primary care
provider/ED if salbutamol has to be given more often than
every 4 h for increased work of breathing/severe cough
and if the respiratory status interferes with usual play/nor-
mal speech or activity.
Outcome measures
Primary outcome measure
The primary outcome measure is hospitalization (based
on the ED physician’s decision to admit) to an inpatient
unit within 24 h of the start of the experimental therapy
for persistent respiratory distress or for supplemental
oxygen. Children deemed to be admitted but who due to
lack of bed availability are never transferred to the ward
will be analyzed as hospitalized. Extended ED stays with-
out a decision to admit are not considered admitted.
Secondary outcome measures
The two groups will also be compared with respect to
the following:
a. All cause hospitalization rate by 24 h to examine Mg
impact on side effects, such as hypotension
necessitating admission.
b. Changes in the PRAM, respiratory rate, and oxygen
saturation from the start of the first experimental
nebulization to 60, 120, 180, and 240 min and the
changes in the blood pressure from the first
experimental nebulization to 20, 40, 60, 120, 180,
and 240 min.
c. Number of salbutamol treatments within 240 min of
starting study medication.
d. An association between hospitalization and age, sex,
symptom duration <24 h [60], pre-randomization
PRAM score, personal history of atopy, and “acute
viral induced wheeze” phenotype [75–81].
Other outcomes
Major side effects such as hypotension (systolic blood
pressure below the 5th percentile for age) or apnea is
tracked as is admission to ICU for airway stabilization.
The clinical outcomes are measured by trained study
nurses in the ED. The research nurses also ascertain
subsequent return visits/hospitalizations from the tele-
phone follow-ups according to standardized interviewing
techniques, as well as from a review of the patient health
records at 72 h.
Sample size
The sample size calculation is based on the targeted
minimal significant between-group difference in propor-
tions of hospitalizations of 10 %, which has previously
been shown to impact treatment decisions. The esti-
mated probability of hospitalization is based on our fully
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blinded pilot data (pilot patients form an integral part of
this trial), where the overall hospitalization rate is close
to 50 %. This is a superiority study in which the adop-
tion of the Mg therapy can only be recommended for fu-
ture practice if the probability of the primary outcome
in the Mg group is significantly lower than in the pla-
cebo group. With 408 patients per arm (816 in total), a
two-sided test with a type I error of 0.05 will have 80 %
power to achieve statistical significance if Mg therapy re-
duces the probability of hospitalization from 50 to 40 %
(that is, absolute reduction of 10 %) [82].
Analyses
Primary analysis
The proportion of patients hospitalized will be compared
between treatment groups using a two-sided Fisher’s
exact test at the 5 % level. An intention-to-treat analysis
will be used with all randomized participants included in
the analysis as part of the groups to which they were
randomized regardless of whether they completed the
study medication or not.
Secondary analysis
Secondary analysis will include the following:
a) A Fisher’s exact test to compare the rates of all
cause admissions in the two arms.
b) A repeated measures ANOVA to compare treatment
arms with respect to the PRAM score, respiratory
rate, heart rate, oxygen saturation, and blood
pressure over time. Baseline values will be added to
the model as a covariate.
c) A Poisson model will be used to compare the
number of salbutamol treatments used in the ED in
the regression analysis of the two study arms,
including interaction terms with the treatment
group, which will be used to examine the subgroup
effects with respect to the primary outcome. The
following variables will be used to define subgroups:
age, sex, pre-randomization PRAM score, and per-
sonal history of atopy. The statistical tests of hy-
potheses for the secondary outcomes a) through d)
will be two-sided at the 0.00625 level to account for
the issue of multiple testing and to maintain an over-
all type 1 error of 0.05.
Interim analysis
To assure safety, one planned interim analysis will be
conducted on the first 200 patients randomized (a quar-
ter through the study) conducted by a statistician not in-
volved in the trial and evaluated by the independent data
safety monitoring board. The interim analysis will be a
one-sided test of the null hypothesis of no difference
versus the alternative hypothesis that the probability of
hospitalization is higher on Mg therapy at the 0.01 level.
That is, we are looking for evidence that Mg therapy is
less effective, and the trial will be stopped at an interim
analysis only if the null hypothesis is rejected in favor of
the control arm. Therefore, the interim analysis is only
for safety and not for efficacy, and it will not increase
the probability of erroneously rejecting the null hypoth-
esis in favor of Mg therapy at the final analysis. The rea-
son we are doing one-sided (for harm) interim analysis
is because if there is early strong evidence that Mg in-
creases the probability of hospital admission, we want to
stop the trial. On the other hand, we do not want to stop
the trial early for benefit because a smaller sample size
will not be convincing.
Safety
Magnesium blocks the neuromuscular transmission and
acts as a CNS depressant. Therefore, the theoretical ad-
verse effects with IV Mg may include a transient drop in
blood pressure or apnea [83]. The potential for these
problems after nebulized Mg is lower than with IV Mg
because this treatment route will result in a lower sys-
temic delivery of Mg (1/4 of the IV dose) and a lower
systemic effect. Since hypotension is the only major side
effect of IV Mg occurring with appreciable frequency, all
patients are monitored using continuous automated
blood pressure devices, and if the systolic blood pressure
drops below 5th percentile for age, the study will be
stopped, treatment given as necessary, and the DSMC
will be notified. Of note, a recent Cochrane review of
896 patients given inhaled Mg confirmed the safety of
this agent [59]. No child in this study had experienced
hypotension or apnea.
All adverse events are being reported to the Hospital
for Sick Children Research Ethics Board according to
the Hospital for Sick Children’s adverse event reporting
requirements. Adverse events will be classified as mild,
moderate or severe and as expected or unexpected. Ex-
pected adverse events will include cough, respiratory dis-
tress, asthma-related hospitalization, IV insertion, sinus
tachycardia and bitter/salty taste of the experimental so-
lution. Adverse reactions are managed according to the
standard clinical management practices. Furthermore,
we plan to document episodes of severe cough necessi-
tating interruption of the experimental therapy for more
than approximately 3 min to examine the safety profile
of magnesium.
All serious, unexpected adverse drug reactions to the
study medication will be reported to Health Canada
within 15 calendar days, and those resulting in death or
life-threatening events, within 7 calendar days. Serious
adverse events include ICU admission, hypotension <5th
percentile for age, apnea, and any other medical event
which may jeopardize the patients.
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Due to the osmolarity of the study solutions being well
under 500 mOsm/L throughout nebulization and co-
administration of salbutamol, we do not anticipate side
effects due to the aforementioned composition of the
study solutions. However, should the highly unlikely
event of respiratory deterioration occur, the experimen-
tal therapy will be discontinued, appropriate additional
treatment started, and the event will be reported to the
DSMC within 48 h. Salbutamol may cause tachycardia,
and this has been the case in many children enrolled to
date. However, this has been uniformly well tolerated,
and no patient has had to stop/interrupt experimental
therapy due to this issue.
The Data Safety and Monitoring Committee (DSMC)
consists of a non-study biostatistician, a researcher, and
a child health scientist, specifically Dr. Annie Dupuis,
Dr. Neil Sweezey, Dr. Patricia Parkin. The members of
this committee are not collaborators of this trial. They
are notified of all serious adverse events by the study co-
ordinator within 48 h. The DSMC meets once per
asthma season or ad hoc if necessary.
Trial management
The Hospital for Sick Children Research Institute will
act as a central repository for all study data and will be
responsible for study data management technology and
clinical data management services. Dr. Willan will
supervise all data analyses. Dr. Schuh takes overall re-
sponsibility for the study. The study has a Steering Com-
mittee which includes senior research team members:
Dr. Nathan Kuppermann (past chair of Pediatric Emer-
gency Children’s Research Network), Dr. Joseph Zorc
(senior ED clinician investigator), Dr. Amy C. Plint (past
chair of PERC) and Dr. Allan L. Coates (expert in in-
haled drug delivery).
Discussion
If effective, inhaled Mg will represent an effective strat-
egy to minimize morbidity in pediatric refractory acute
asthma. Furthermore, the potential for side effects in this
study can reasonably be expected to be low, since the in-
haled delivery route will result in a lower systemic deliv-
ery of magnesium, a lower systemic effect, and a
substantially enhanced margin of safety compared to the
intravenous administration. To ensure study safety, all
severe adverse events will be reported to the Research
Ethics Board and the Data Safety and Monitoring Com-
mittee as well as to the Steering Committee. A safety in-
terim analysis is planned after the first 200 patients have
been randomized and appropriate unblinding procedures
have been defined.
Future dissemination of results will include knowledge
translation, incorporation into a Cochrane Review,
presentation at scientific meetings, and a peer-reviewed
publication.
We plan to disseminate the results of this study widely
and rapidly to all relevant stakeholders. This will be ac-
complished via the Pediatric Emergency Research
Canada (PERC) network, which has a unique partner-
ship with the Translating Research Emergency Know-
ledge for Kids (TREKK) group, encompassing 36 general
EDs across Canada and 12 PERC sites. In addition, the
PERC network is part of the worldwide Pediatric Emer-
gency Research Network (PERN), consisting of 122 hos-
pitals on five continents.
Trial status
As of 15 September 2015, 207 children had been
enrolled.
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